Clinical Trials Logo

Dedifferentiated Chondrosarcoma clinical trials

View clinical trials related to Dedifferentiated Chondrosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04458922 Active, not recruiting - Clinical trials for Dedifferentiated Chondrosarcoma

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03449108 Active, not recruiting - Clinical trials for Triple Negative Breast Cancer

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. LN-145-S1 is made using a modified process that chooses a specific portion of the T-cells. The T cells may specifically recognize, target, and kill the tumor cells.

NCT ID: NCT01267955 Active, not recruiting - Clinical trials for Mesenchymal Chondrosarcoma

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Start date: December 21, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.